Analyzing kinetic signaling data for G-protein-coupled receptors by Hoare, Sam R. J. et al.
1Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:12263  | https://doi.org/10.1038/s41598-020-67844-3
www.nature.com/scientificreports
Analyzing kinetic signaling data 
for G‑protein‑coupled receptors
Sam R. J. Hoare1*, paul H. tewson2, Anne Marie Quinn2, thomas e. Hughes2 & 
Lloyd J. Bridge3
In classical pharmacology, bioassay data are fit to general equations (e.g. the dose response equation) 
to determine empirical drug parameters (e.g.  EC50 and  emax), which are then used to calculate chemical 
parameters such as affinity and efficacy. Here we used a similar approach for kinetic, time course 
signaling data, to allow empirical and chemical definition of signaling by G-protein-coupled receptors 
in kinetic terms. Experimental data are analyzed using general time course equations (model-free 
approach) and mechanistic model equations (mechanistic approach) in the commonly-used curve-
fitting program, GraphPad Prism. A literature survey indicated signaling time course data usually 
conform to one of four curve shapes: the straight line, association exponential curve, rise-and-fall 
to zero curve, and rise-and-fall to steady-state curve. In the model-free approach, the initial rate of 
signaling is quantified and this is done by curve-fitting to the whole time course, avoiding the need to 
select the linear part of the curve. It is shown that the four shapes are consistent with a mechanistic 
model of signaling, based on enzyme kinetics, with the shape defined by the regulation of signaling 
mechanisms (e.g. receptor desensitization, signal degradation). Signaling efficacy is the initial rate 
of signaling by agonist-occupied receptor (kτ), simply the rate of signal generation before it becomes 
affected by regulation mechanisms, measurable using the model-free analysis. Regulation of signaling 
parameters such as the receptor desensitization rate constant can be estimated if the mechanism is 
known. this study extends the empirical and mechanistic approach used in classical pharmacology to 
kinetic signaling data, facilitating optimization of new therapeutics in kinetic terms.
Pharmacological data analysis provides the drug activity parameters used to optimize the biological activity of 
new therapeutics and to identify mechanisms of receptor-mediated signal transduction for G-protein-coupled 
receptors (GPCRs). In the typical analysis process, activity is measured at various drug concentrations and the 
data fit to a concentration–response equation by curve fitting, for example to a sigmoid curve  equation1–3. This 
yields empirical drug parameters, usually the potency  (EC50) and a measure of the maximal signaling capacity 
 (Emax). This analysis is described as “Model-free” because it makes minimal assumptions regarding the mecha-
nism of signal transduction. These parameters can then be used to calculate mechanistic drug parameters that 
define the effect of the drug on the system in chemical terms (e.g. efficacy and macroscopic affinity)3–8. These 
chemical parameters aid the translation of drug effect measurement from in vitro test systems to animal models 
and human disease, for example by minimizing the effect of tissue-specific parameters on the quantification of 
drug activity. Biased agonism measurement is an example of this process currently in use by many laboratories. 
Signaling assay data are fit to concentration–response equations and the empirical parameters  EC50 and  Emax 
used to calculate mechanistic parameters of biased signaling, such as transducer coefficients and log efficacy 
ratios (reviewed  in9).
The manner in which GPCR signaling changes over time, i.e. the kinetics/dynamics of response, is currently of 
considerable interest in quantitative pharmacology. The time course of GPCR response has been measured since 
the earliest studies of muscle  contraction1, through the discovery of G-protein-mediated  signaling10, the applica-
tion of  Ca2+ indicator  dyes11, and the most recent advances in biosensor technology that enable high-throughput 
signaling kinetic  analysis12–14. Measuring the time course of receptor signaling revealed fundamental mecha-
nisms of GPCR function. The classic rise-and-fall time course of cAMP in S49 cells indicated desensitization 
of β2 adrenoceptor  signaling15. Sustained signaling after agonist washout by parathyroid hormone, sphingosine 
1-phosphate and thyroid-stimulating hormone receptors revealed signaling by internalized  receptors16–18, a new 
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spatiotemporal paradigm of GPCR signaling of potential therapeutic  utility19–23. Signaling kinetics can also affect 
quantification of drug activity. Of potential concern, drug effect can be dependent on the time point at which 
the response is measured. For example, biased signaling of the  D2 dopamine receptor was shown to be time-
dependent24. For the  CB1 receptor, the potency for internalization increased over  time25. For  AT1 angiotensin 
receptor-mediated arrestin recruitment the potency increased over time, as did the  Emax of partial  agonists26. 
Finally, differences of signaling kinetics can be a manifestation of structural differences of receptor-ligand inter-
action. For example, the nonpeptide GLP-1 receptor agonist TT-OAD2 protrudes outside of the receptor core, 
interacting with lipid, potentially explaining the unusually slow signaling kinetics of the  ligand27.
A data analysis framework for time course data of GPCR signaling would enable the quantification of efficacy 
in kinetic terms. One way to do this is to measure the initial rate of signaling, analogous to the initial rate of 
enzyme  activity26,28–32, an approach recently applied to receptor receptor–arrestin  interaction26. Kinetic analysis 
could also enable measurement of regulation of signaling parameters, such as the rate constant for receptor 
desensitization. At present, time course data for GPCR signaling are rarely analyzed by curve fitting to estimate 
kinetic pharmacological parameters (in contrast to the near-universal application of curve fitting to concentra-
tion-dependence data). The absence of curve fitting to time course data might be resulting in lost opportunities, 
particularly for biosensor assay modalities in which the time course data are collected by default. Kinetic insights 
into GPCR function might be being missed. Potential benefits of the kinetic dimension to ligand optimization 
could be going unrealized. The goal of this study was to develop a straightforward data analysis framework for 
quantifying the kinetics of GPCR signaling, enabling investigators to measure kinetic drug parameters useful 
for practical pharmacological application.
Results
In this study, a data analysis framework for curve fitting of time course data was developed for GPCR signaling 
kinetics/dynamics. First, we identified the types of time course curve shape by conducting a comprehensive 
literature survey. It was discovered that the curve shapes, more precisely the temporal profiles, conform to a 
limited number of shapes (four). This survey also showed how the time course is shaped by regulation of signal-
ing mechanisms (e.g. receptor desensitization and response degradation). The shapes were defined by simple 
equations that can be used to analyze time course data using familiar curve-fitting software (e.g. Prism, Graph-
Pad Software, Inc., San Diego CA). This analysis yields a kinetic drug parameter, the initial rate of signaling by 
agonist-occupied receptor, that defines efficacy as the rate of signal generation before it is impacted by regulation 
of signaling mechanisms. This parameter, termed kτ, provides a biologically meaningful and intuitive metric of 
the kinetics of signal transduction. Finally, mechanistic models are applied to the time course data using a kinetic 
mechanistic model of agonism developed  previously33, and extended here to incorporate receptor desensitization 
and sustained signaling by internalized receptors. This analysis demonstrated the model-free equations emerge 
as general forms of the mechanistic equations, providing a mechanistic foundation for the analysis approach.
Literature survey of time course shapes. The first step in analyzing biological activity data is visual 
inspection of the data. In pharmacological data analysis, this led to the realization that concentration–response 
data are usually described by a sigmoid curve (when the x axis is the logarithm of ligand concentration)1,2. Here 
we surveyed the GPCR signaling literature for time course data. The survey was designed to be comprehen-
sive, spanning (1) The full range of heterotrimeric G-protein classes  (Gs,  Gi,  Gq/11,  G12/13); (2) response times of 
milliseconds to hours; (3) Proximity to the receptor, from direct receptor interaction (G-protein and arrestin) 
to downstream signals (e.g. cell contraction/relaxation and gene expression); (4) Types of response, including 
chemical (second messengers), mechanical (cell structure change), electrical (ion channel currents) and genetic 
(gene expression). This was done for experiments when the receptor was exposed continuously to the agonist, 
i.e. agonist washout experiments were not considered.
Within this survey, the large majority of time course profiles conformed to one of four shapes (Fig. 1). Each 
shape is defined by a corresponding equation (Eqs. 1–4 in Methods). The equations are amenable to straightfor-
ward curve-fitting analysis in familiar software. The shapes are, in order of increasing complexity:
1. The straight line (Fig. 1a). Response increases continuously over time at a constant rate (defined by Eq. 1).
2. The association exponential curve (Fig. 1b, Eq. 2). Initially, response increases rapidly, being almost linear. 
The response then slows then finally approaches a plateau at which the response level remains constant over 
time.
3. The rise-and-fall to baseline curve (Fig. 1c, Eq. 3). The first phase resembles the association exponential 
curve – response increases rapidly at first, then slows. The response then reaches a peak level. Subsequently, 
the response level decreases and finally falls back to the baseline level, i.e. the level before addition of ligand.
4. The rise-and-fall to steady-state curve (Fig. 1d, Eq. 4). Response rises and falls as for the rise-and-fall to 
baseline curve. However, the response declines to a steady-state level, above that of the baseline level before 
addition of ligand.
Straight line time course profile. The straight line profile was evident in second messenger responses under a 
specific condition—when signaling was unregulated, i.e. when regulation of signaling mechanisms were blocked 
(Fig. 2). GPCR signaling is regulated over the short term by two primary mechanisms: receptor desensitization 
(involving receptor phosphorylation and subsequent arrestin binding)34–36 and degradation of the response (for 
example metabolism of second messengers)37–39. The straight line profile was observed when both mechanisms 
were blocked. For example,  AT1 angiotensin receptor-stimulated inositol phosphates (IP) production was linear 
when desensitization was blocked (using arrestin knock out cells) and response degradation was blocked (using 
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 Li+ to block IP breakdown) (Fig. 2a)40. The same result was obtained for the proteinase-activated receptor PAR1 
receptor (see Fig. 2a  in41). A second example is provided by the  GnRH1 receptor, which lacks a C-terminal tail 
and so does not interact with  arrestin42. A linear time course was observed, in the presence of  Li+ (Fig. 2b)43. (See 
also Fig. 1a,b  in44 and Fig. 3  in45.) A third example is provided by the glucagon receptor. A linear time course of 
cAMP accumulation was observed in hepatic  membranes46. The membranes lacked cAMP phosphodiesterase 
 activity47, and likely lacked receptor desensitization components owing to extensive washing of the preparation 
(Fig. 2c).
Linear time course data were also observed for long duration responses, far downstream, at the level of DNA, 
specifically gene expression and DNA synthesis (Supplementary Fig. S1)48,49. In these responses there was a delay 
before the onset of the response. This has been rationalized for gene expression responses by a need for a build-up 
of signal transduction intermediates to a threshold level that then initiates the  process48.
Association exponential time course profile. The association exponential profile was the most commonly-
observed time course shape, especially for second messenger molecules such as cAMP and inositol phosphates, 
but also for a variety of other signals, from upstream events such as arrestin recruitment to downstream cellular 
functions such as muscle cell relaxation (Fig. 3, Supplementary Fig. S2). Regarding regulation of signaling, the 
profile was evident when one of the two mechanisms was operative and one was blocked (the mechanisms 
being receptor desensitization and response degradation). Examples include  AT1 receptor-stimulated IP produc-
tion, with receptor desensitization in operation (arrestin wild-type cells) but without response degradation (IP 
metabolism blocked by  Li+) (Fig. 3a)40;  GnRH1 receptor-simulated IP production with response degradation in 
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Figure 1.  Time course profile shapes typically observed for GPCRs. (a) Straight line. (b) Association 
exponential curve. (c) Rise-and-fall to baseline curve. (d) Rise-and-fall to steady-state curve. Data for (a) 
were simulated using Eq. (1) (Slope, 6.6 response units min−1), (b) with Eq. (2) (SSR, 200 response units; k , 
0.30 min−1), (c) with Eq. (3) ( C , 120 response units min−1; k1 , 0.25 min−1; k2 , 0.20 min−1) and (d) with Eq. (4) 
(SSR, 75 response units; D , 25 (note D is unitless); k1 , 0.25 min−1; k2 , 0.20 min−1). The Baseline parameter in each 
equation was set to zero.
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operation (no  Li+ present) but without receptor desensitization (the GnRH receptor lacking a C-terminal tail) 
(Fig. 3b)45; and β2 adrenoceptor-stimulated cAMP generation with response degradation (cAMP metabolism) 
but without receptor desensitization (arrestin knockout cells) (Fig. 3c)53.
The association exponential profile was observed in direct receptor-transducer interaction assays, includ-
ing receptor-G-protein interaction and receptor-arrestin interaction (Supplementary Fig. S2a,b)26,54. This was 
expected; mechanistically, the response is likely resultant from a bimolecular interaction and the association 
exponential equation is a general form of the familiar bimolecular association kinetics equation. G-protein activa-
tion was also described by the profile, measured by  [35S]GTPγS binding, or by a G-protein activation biosensor 
(Supplementary Fig. S2c,d)54,55. cAMP production responses also conform to the profile, both stimulation (Sup-
plementary Fig. S2e) and inhibition (Supplementary Fig. S2f)56,57. A specialized signaling pathway, β-catenin 
stabilization via the Wnt-Frizzled system, was also described by the  profile58 (Supplementary Fig. S2g). Electrical 
signaling was also described by the association exponential profile, as shown by GIRK channel gating in Xenopus 
Figure 2.  Linear time course profile examples of GPCR signaling. In all cases, regulation of signaling activity 
(receptor desensitization and response degradation) was minimized as described in the text boxes. (a) Inositol 
phosphates production via the  AT1 receptor stimulated by 100 nM AngII in fibroblasts from arrestin knock-out 
mice (from Fig. 3c  of40). (b) Inositol phosphates production via the  GnRH1 receptor stimulated by 1 μM GnRH 
in HEK293 cells (from Fig. 4a  of43). (c) cAMP production in hepatic membranes stimulated by 2 μM glucagon 
(data from Fig. 1  of46, basal response in the absence of glucagon subtracted). Note the membrane preparation 
used lacks cAMP phosphodiesterase  activity47. Data were fit to the straight line equation (Eq. 1) using Prism  850. 
The Slope value on the panels, which is equal to the initial rate and kτ, is the fitted value ± the fit  SEM51,52.
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oocytes (Supplementary Fig. S2h)59. In the final example, a downstream cellular response was found to conform 
to the profile, relaxation of human airway smooth muscle cells via the β2 adrenoceptor (Supplementary Fig. S2i)60.
Rise‑and‑fall to baseline time course profile. The rise-and-fall to baseline profile is a classic curve shape in phar-
macology, leading to the definition of “Fade” (decline in the response to a continuous application of  agonist62) 
and the discovery of the underlying mechanism (regulation of signaling processes, especially receptor desensiti-
zation)15,36. An equation was identified that defines this shape, here termed the rise-and-fall to baseline equation 
(Eq. 3). This equation is familiar in pharmacokinetics, being the equation defining drug concentration in the 
oral dosing absorption and elimination  model63,64. We have loaded it into a custom Prism template, “Signaling 
kinetic model-free equations” available in the supplementary files.
Figure 3.  Association exponential time course profile examples of GPCR signaling. In all cases, one of the 
regulation of signaling mechanisms was in operation and one was blocked (see text boxes). Data were fit to 
the association exponential equation (Eq. 2) using Prism 8 61. (a) Inositol phosphates production via the  AT1 
receptor stimulated by 100 nM AngII in fibroblasts from wild-type mice (from Fig. 3c  of40). (b)  IP3 production 
via the  GnRH1 receptor stimulated by 85 nM GnRH in rat granulosa cells in the absence of  Li+ (from Fig. 3  of45). 
(c) cAMP production via the β2 adrenoceptor stimulated by 1 μM isoproterenol in fibroblasts from arrestin 
knock-out mice (data from Fig. 5d  of53). Note a slight decline was observed at later time points (> 10 min), 
which have been excluded from the figure. The fitted values SSR (steady-state response) and k (the rate constant) 
are the fitted value ± the fit  SEM51,52. The initial rate, equal to kτ, was calculated as the steady state response (SSR) 
multiplied by the rate constant k.
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Two examples for second messenger molecules are shown in Fig. 4, diacylglycerol production via the  AT1 
receptor (Fig. 4a)65 and cAMP production via the β2  adrenoceptor53 (Fig. 4b). In both studies the mechanisms 
underlying the curve shape were investigated. The rise-and-fall to baseline mechanism was evident when both 
regulation of signaling mechanisms were operative, i.e. when there were no experimental manipulations of 
receptor desensitization or degradation of the response. When the regulation mechanisms were manipulated, the 
shape of the curve changed. When receptor desensitization was blocked or attenuated, the resulting curve shape 
approached the association exponential curve, as shown in Fig. 2a of the original study for the  AT1  receptor65 and 
Fig. 3c for the β2 adrenoceptor. Response degradation was in operation, demonstrated for the β2 adrenoceptor by 
the effect of phosphodiesterase  inhibition53 and assumed for the  AT1 receptor because diacylglycerol is typically 
cleared rapidly by diacylglycerol  kinases38.
The rise-and-fall to baseline response is also well known in calcium signaling, representing the change of 
cytoplasmic  Ca2+ concentration on stimulation by GPCR agonists (usually when there is no extracellular  Ca2+ in 
the assay). An unusual regulation mechanism is involved in  Ca2+ signaling via intracellular stores. The amount 
of cytoplasmic  Ca2+ that can be obtained is limited by the amount of  Ca2+ in the intracellular  stores66,67. Deple-
tion of  Ca2+ in the store as it is being released into the cytoplasm limits the amount and rate of cytoplasmic  Ca2+ 
release. This regulation mechanism can be described as depletion of response  precursor33. The response is also 
regulated by clearance of cytoplasmic  Ca2+ out of the  cell68,69. This can be described as response degradation. 
These two regulation processes result in the rise-and-fall to baseline profile as described  previously33. An exam-
ple is provided by GnRH-stimulated  Ca2+ mobilization in pituitary gonadotrophs, as shown in Fig. 4c70. Other 
Figure 4.  Rise-and-fall to baseline time course profile examples of GPCR signaling. In all cases, none of 
the regulation of signaling mechanisms were manipulated and the model underlying the curve shape can be 
inferred. Data were fit to Eq. (7) in all cases. (a) Diacylglycerol production via the  AT1 angiotensin receptor 
stimulated by 100 nM AngII (data from Fig. 1c  of65). (b) cAMP production via the β2 adrenoceptor stimulated 
by 10 μM isoproterenol (data from Fig. 3a  of53). (c) Intracellular  Ca2+ mobilization via the  GnRH1 receptor 
stimulated by 100 nM GnRH in the absence of extracellular  Ca2+ (data from Fig. 1a, absence of extracellular 
 Ca2+,  of70). Note in (b) the fitting procedure involved minimization of outlier contribution to the fit (“Robust 
regression”)74, which precluded estimation of the fitted parameter error and  R2 values (see Supplementary file 
“Curve fit results” for details). The initial rate, equal to kτ, is the fitted parameter C.
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receptors giving this profile include the BB1  receptor71 and  AT1  receptor26. It is important to note that other 
time course shapes are observed for cytoplasmic  Ca2+ mobilization, including the rise-and-fall to steady-state 
curve (considered separately below), and calcium oscillations and  waves72,73. In addition, rise-and-fall profiles 
are observed in  Ca2+ responses which are not fit well by the rise-and-fall equations used in this study (e.g. in 
Supplementary Fig. S3).
Rise‑and‑fall to steady‑state time course profile. A second rise-and-fall curve shape is encountered in GPCR 
signaling in which the response, after rising to the peak, falls to a plateau level of response which is above base-
line, i.e. response declines to a steady-state after peaking. Examples of this shape are shown in Fig. 5. In this study, 
an equation was identified that describes these data, termed the rise-and-fall to steady-state equation (Eq. 4). 
This equation was identified as a general form of explicit GPCR signaling mechanism equations, as described 
in Appendix 2. These mechanisms are more complex than the simplest mechanisms considered  previously33 
and include recently-discovered mechanisms, such as persistent signaling by internalized  receptors16,17. These 
mechanisms are considered below (“More complex models”). We have loaded the equation into a custom Prism 
template, “Signaling kinetic model-free equations” available in the supplementary files.
The most commonly-encountered example was calcium mobilization, the increase of cytoplasmic  Ca2+ upon 
application of the GPCR agonist. A representative example is shown in Fig. 5a, cytoplasmic  Ca2+ concentration 
stimulated by GnRH via the  GnRH1  receptor70. It is well known that the cytoplasmic  Ca2+ level usually reaches a 
plateau after sustained application of the agonist, particularly when  Ca2+ is included in the extracellular medium. 
Under this condition,  Ca2+ can re-enter the cell and this can result in a steady-state being reached between the 
numerous processes controlling cytoplasmic  Ca2+  concentration68,72,73,75. This mechanism can be represented in 
the context of the regulation of signaling mechanisms as a reformation of the response from the response decay 
product, in this case reappearance of cytoplasmic  Ca2+ from the extracellular space. This mechanism was formu-
lated in Appendix 2.3.3 (see supplementary files). This mechanism is described in general form by the rise-and-
fall to steady-state equation (Eq. 3) and in explicit form by Eq. (15). Data are analyzed by the general form (see 
“Measuring the initial rate from curve fit parameters” below) and explicit form (“Measuring model parameters”).
The rise-and-fall to steady-state profile is also commonly observed in numerous downstream signaling 
responses, examples of which are shown in Fig. 5: ERK1/2 phosphorylation by lysophosphatidic  acid76, and 
protein kinase C and Rho activation via the  AT1  receptor77. In some cases, the data fit the rise-and-fall to steady-
state equation well (high  R2 value) but the fitted parameters were ambiguous, a scenario encountered when the 
two rate constant values were almost equal. An example is provided in Supplementary Fig. S4. This observation 
requires further investigation, for example using structural identifiability analysis.
initial rate measurement using model‑free analysis. In order for time course analysis to be useful 
for pharmacological investigations, pharmacological parameters need to be extracted from the data that capture 
the temporal dimension of activity. One kinetic parameter used routinely for another target class (enzymes) and 
occasionally for GPCRs is the initial rate of activity. This is the rate at the earliest part of the time course, when 
the response increases linearly over time. This parameter offers several benefits. (1) It is a biologically-meaning-
ful descriptor of signaling activity. (2) In principle, the initial rate is effectively a pure efficacy parameter, being 
the rate of signal generation before it is affected by regulation of signaling mechanisms, which affect the shape of 
the later part of the time course. This is formally demonstrated using the kinetic pharmacological model below. 
(3) From a practical perspective, the initial rate provides a single parameter, as opposed to multiple parameters, 
of drug efficacy, simplifying application to ligand optimization in medicinal chemistry projects. (4) The initial 
rate can be determined regardless of the shape of the time course, enabling comparison of a ligand’s efficacy 
between responses with different temporal profiles (see below). We recently applied the initial rate approach 
to arrestin–receptor interaction, a special case in which there was no signal  transduction26. Here it is applied 
universally to GPCR signaling responses. It is important to note the initial rate is system-dependent because it is 
dependent on system parameters such as the receptor and effector concentrations (see “Comparison of models 
with model-free analysis” below).
Measuring the initial rate from curve fit parameters. For curved time course data, the initial rate is often meas-
ured by assessing which data points lie on the linear portion at the start of the curve, then fitting a straight line 
equation to those points. Here a more efficient method is developed. The entire time course is fit to the equation 
that defines the curve, then the initial rate calculated from the fitted parameters. This requires an additional 
equation that defines the initial rate ( IR ) in terms of the fitted parameters. This equation was obtained here for 
each of the time course shapes, as the limit of the time course equation as time approaches zero (the formal 
definition of the initial rate condition) (Appendix 1, see supplementary files):
Straight line, from Eq. (1):
Association exponential, from Eq. (2):
Rise-and-fall to baseline, from Eq. (3):
Rise-and-fall to steady-state, from Eq. (4):
IR = Slope
IR = SSR.k
IR = C
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This method was used to quantify the initial rate of signaling for the responses in Figs. 2, 3, 4 and 5 and Sup-
plementary Figs. S1, S2. Data were fit to the appropriate time course equation using Prism 8. The fitted parameter 
values and the fitted standard error are shown in the panels of the figures. For linear and association exponential 
profiles data were analyzed using built-in equations provided with the software. For the rise-and-fall profiles, 
user-entered custom equations were used. (A ready-to-use Prism template containing these equations, “Signal-
ing kinetic model-free equations,” is provided in the supplementary files.) In some cases, the signal initiation 
time was a variable in the equation (see Eqs. 5–9), allowing for delay between addition of ligand and initiation of 
signal (e.g. in gene expression assays, Supplementary Fig. S1), or accommodating the scenario where the ligand 
addition time is not precisely defined. The data presented in this study were fit well by the equations; in all but 
one case, the correlation coefficient was > 0.95, and the standard error of the fit parameters was typically < 10% 
of the fitted value (see “Curve fit results” Excel file in Supporting Material). With two exceptions, data were fit 
well using the default fitting method of Prism 8 (least squares regression with medium convergence  criteria78). 
The exceptions were the rise-and-fall fit in Fig. 4b (cAMP production via the β2 adrenoceptor without phospho-
diesterase inhibition) and Fig. 5b (LPA-stimulated ERK phosphorylation). In these cases, the default method 
IR = SSR.(Dk1 − (D− 1)k2)
Figure 5.  Rise-and-fall to steady-state time course profile examples of GPCR signaling. (a) Intracellular 
 Ca2+ mobilization via the  GnRH1 receptor stimulated by 100 nM GnRH in the presence of extracellular 
 Ca2+, an example of the precursor depletion with response degradation to steady-state model (data from 
Fig. 1a, presence of extracellular  Ca2+,  of70). (b) ERK1/2 phosphorylation via the  LPA1 receptor stimulated 
by 10 μM LPA (data from Fig. 4a  of76, fit to Eq. (4) with baseline fixed at 1.0) (c) PKC activation and (d) 
Rho activation by the  AT1 receptor in vascular smooth muscle cells stimulated by 100 nM AngII (data from 
Fig. 3a,b, respectively,  of77, fit to Eq. 8). Note in (b) the fitting procedure involved minimization of outlier 
contribution to the fit (“Robust regression”)74, which precluded estimation of  R2 values. Fitted parameter 
values are given in the file “Curve fit results” in Supporting Material. Initial rate was calculated using the 
equation, Initial rate = SSR × (Dk1 − (D − 1)k2) (See Appendix 1.1). Data in (a) were also analyzed using the 
mechanism equation for precursor depletion and response degradation to steady-state (Eq. 17 in Methods). The 
fitted curve overlies that of the rise-and-fall to steady-state fit.
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yielded an ambiguous  fit79 (see “Curve fit results” Excel file in Supporting Material), which was resolved using 
the “Robust regression” option which minimizes the contribution of outliers to the  fit74.
The initial rate value was then calculated from the fitted parameter estimates using the equations above. Note 
the simplicity of obtaining the initial rate in most cases. For example, for the association exponential curve, the 
initial rate is simply the rate constant multiplied by the steady-state response. For the rise-and-fall to baseline 
curve, it is simply the value of the fitted parameter C . The calculated initial rate values are shown in the figures 
(Figs. 2, 3, 4 and 5, Supplementary Figs. S1, S2). A maximally-stimulating concentration of agonist was employed 
in all the examples provided. Under this condition, the initial rate is the efficacy parameter of the agonist in 
kinetic terms, here termed IRmax.
It is also possible to perform global fitting of the signaling kinetic data with time and ligand concentrations 
as independent variables. This can require knowledge of which parameters in the model are dependent on the 
ligand concentration, which in turn can require knowledge of the underlying mechanism. The methods used 
for this approach are described in  ref33.
Comparison with single time point analysis. Historically, pharmacological responses have been measured for 
multiple concentrations of ligand at a single time point and ligand activity described by the potency (e.g.  EC50) 
and maximal response  (Emax). Here we compared this single time point concentration–response analysis with 
a concentration–response analysis of the initial rate of signaling. For this purpose, we measured cAMP accu-
mulation and arrestin recruitment via the  V2 vasopressin receptor. This receptor is activated by two cognate 
endogenous ligands, vasopressin and  oxytocin80. The receptor is well known to couple stably to arrestin when 
bound by vasopressin (a so-called class B arrestin binding  profile34). The receptor is activated by two endogenous 
ligands, vasopressin and oxytocin, that differ in their spatiotemporal mechanisms of  signaling81. Genetically-
encoded biosensors were used to quantify these responses in real time in live cells expressing the  receptor26,82, 
as described in Methods.
Figure 6 shows the time courses for a range of concentrations of the two ligands for cAMP accumulation 
and arrestin recruitment. In all cases, the time course data were fit well by the association exponential equation 
(Eq. 6, Fig. 6, see also “Curve fit results” Excel file in Supporting Material). From the fitted parameters, the initial 
rate was calculated. This was done by multiplying the steady-state response by the rate constant as described 
above (see “Curve fit results” Excel file for values). The initial rate for maximally-stimulating concentrations of 
ligand is shown graphically by the dashed straight lines in Fig. 6c,f. The concentration–response of the initial 
rate was then evaluated, as shown in Fig. 7a. The concentration response was fit well by a standard sigmoid curve 
equation, from which the efficacy and potency of the ligand could be determined (Table 1). The efficacy is the 
maximal initial rate ( IRmax ), i.e. the upper plateau of the curve. The potency is the midpoint concentration of 
the ligand, specifically the concentration of ligand giving an initial rate half of the maximum value. Here this is 
termed  L50 (Table 1).
The concentration–response analysis indicated oxytocin was less active for recruiting arrestin than vasopressin 
(Fig. 7a, Table 1), consistent with a previous  report81. This was manifest as a 6.2-fold lower potency for oxytocin 
compared with vasopressin (580 nM vs 93 nM respectively, − log  L50 values significantly different, Table 1). The 
maximal initial rate of arrestin recruitment ( IRmax ) for oxytocin was value 70% of the vasopressin value but the 
IRmax values were not significantly different (Table 1). These results indicate the weaker arrestin recruitment by 
oxytocin can be accounted for by a lower affinity of oxytocin compared with vasopressin for the arrestin-bound 
receptor. By contrast the two ligands were effectively equivalent for stimulation of cAMP production (Fig. 6c, 
Table 1). These findings imply biased agonism of oxytocin relative to vasopressin (G-protein bias) in terms of 
the initial rate.
Next, data were analyzed using a single time point. A time late in the time course was selected when the 
responses for high concentrations was approaching steady-state (18 min after ligand addition, 22 min after 
the read start, Fig. 6). This reflects a modality in which the assay is left long enough for the maximal signal 
to accumulate, often referred to as an “Endpoint” modality. The concentration–response curves are shown in 
Fig. 7b and results of the sigmoid curve analysis in Table 2. Using this metric, the parameters were slightly dif-
ferent from the initial rate analysis (Fig. 7a, Table 1). Specifically, the maximal response of oxytocin was similar 
to that of vasopressin for both arrestin and cAMP responses. In addition, rather than being uquipotent in the 
cAMP assay, vasopressin was more potent than oxytocin  (L50 of 0.089 and 0.36 nM, − log  L50 values significantly 
different, Table 2). This means that the biased agonism in terms of potency observed in the initial rate analysis 
for oxytocin was not observed in the endpoint modality (since the potency difference for arrestin, 4.0-fold, was 
similar to the potency difference for cAMP, 6.9-fold, Table 2). One possible explanation for this difference is that 
the initial rate for vasopressin in generating cAMP was limited by slow receptor-ligand equilibration, a scenario 
discussed in theoretical terms  previously33 and in the Discussion below. Another difference was that the potency 
for arrestin recruitment was higher using the endpoint approach compared with the initial rate approach (by 
4.4-fold for vasopressin and 3.2-fold for oxytocin, compare Tables 1 and 2). This difference was also observed for 
the  AT1 angiotensin receptor and reflects the kinetic mechanism of arrestin recruitment, as described in ref.26.
Mechanistic pharmacological model of GpcR signaling and regulation kinetics. Recently 
a mechanistic kinetic pharmacological model was developed to quantify GPCR signaling activity in kinetic 
 terms33 that is being applied to understanding signaling efficacy in kinetic  terms8. The model comprises a mini-
mal number of parameters to enable parameter estimation by curve fitting. The approach is macroscopic—ligand 
signaling activity is defined at the level of the whole system, like the operational model of  agonism7. (Numerous 
microscopic systems-biology type models have been developed to simulate GPCR signaling dynamics that quan-
tify each interaction in the signaling  cascade8,53,84–88 but, while they enable close examination of mechanism, 
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Figure 6.  Applying the model free initial rate analysis to  V2 vasopressin receptor-mediated cAMP signaling and 
arrestin recruitment. The time courses of cAMP production (a–c) and arrestin recruitment (d–f) were measured 
using genetically-encoded  biosensors26,82, as described in Methods, for vasopressin and oxytocin. Time course 
data were well fit by the association exponential equation (Eq. 6, with fitted signal initiation time, see fit values in 
“Curve fit results” Excel file in Supporting Material). (c,f) overlay of vasopressin and oxytocin time courses for a 
maximally-stimulating concentration of ligand (32 nM for cAMP, 32 μM for arrestin). The curve fit values were 
used to calculate the initial rate as described in Fig. 7. The dashed lines in (c) and (f) are the initial rates. Data 
points are mean of two or four technical replicates from representative experiments. Error bars are standard 
deviation. The dashed vertical lines indicate the time point used for single time point analysis (Fig. 7b, Table 2).
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Figure 7.  Concentration–response data for cAMP and arrestin response via the  V2 vasopressin receptor, 
comparing initial rate and endpoint methods. (a) Initial rate, calculated from the fits to the time course data 
in Fig. 6 by multiplying the steady-state response by the rate constant value ( SSR × k ). (b) Endpoint response, 
calculated as the response to ligand 18 min after ligand addition. Data were analyzed using a sigmoid curve 
 equation83, providing fitted values of the maximal initial rate ( IRmax , equal to kτ) in (a) or the  Emax at 18 min 
in (b), and the  L50 (concentration of agonist producing 50% of the maximal response). Data were normalized 
by subtracting the fitted background then normalizing to the fitted maximal response to vasopressin. Data 
points are mean ± standard deviation from three independent experiments. Tables 1 and 2 present the curve fit 
parameters and statistical comparisons.
Table 1.  V2 initial rate dose response for cAMP generation and arrestin recruitment stimulated by vasopressin 
and oxytocin via the  V2 vasopressin receptor. The initial rate of the responses were measured using genetically-
encoded  biosensors26,82 as described in Methods. Time course data were analyzed to determine the initial rate 
as described in Fig. 6. The initial rate was then plotted against the ligand concentration (Fig. 7a) and the data 
fit to a sigmoid curve  equation83 to determine the maximal initial rate  (IRmax, the upper plateau, equivalent 
to kτ) and  L50 (concentration of ligand giving an initial rate 50% of  IRmax). Data values are mean ± SEM, 
n = 3. Curve fit results for each experiment are provided in the “Curve fit results” Supplementary file. NFU is 
normalized fluorescence units. Ligand parameters were compared statistically by paired two-tailed t-test, with 
the following p values: a0.346, b0.733, c0.0943, d0.0203.
Ligand
cAMP Arrestin
IRmax, kτ 
NFU min−1 IRmax, kτ % vaso − log  L50  (L50, nM)
IRmax, kτ 
NFU min−1 IRmax, kτ % vaso − log  L50  (L50, nM)
Vasopressin 0.26 ± 0.01a 100 ± 0 9.16 ± 0.20b (0.70) 0.051 ± 0.003c 100 ± 0 7.03 ± 0.06d (93)
Oxytocin 0.24 ± 0.05a 90 ± 8 9.21 ± 0.18b (0.61) 0.035 ± 0.003c 70 ± 9 6.23 ± 0.06d (580)
Table 2.  Endpoint dose response for cAMP generation and arrestin recruitment stimulated by vasopressin 
and oxytocin via the  V2 vasopressin receptor. The responses at a single time point (18 min after ligand 
application, 22 min after experiment initiation) were measured using genetically-encoded  biosensors26,82 as 
described in Methods. See Fig. 6 for raw data. The data were fit to a sigmoid curve  equation83 to determine 
the maximal initial rate  (IRmax, the upper plateau, equivalent to kτ) and  L50 (concentration of ligand giving an 
initial rate 50% of  IRmax). Data values are mean ± SEM, n = 3. Curve fit results for each experiment are provided 
in the “Curve fit results” Supplementary file. NFU is normalized fluorescence units. Ligand parameters were 
compared statistically by paired two-tailed t-test, with the following p values: a0.258, b0.0496, c0.390, d0.0101.
Ligand
cAMP Arrestin
Emax NFU Emax % vaso − log  L50  (L50, nM) Emax NFU Emax % vaso − log  L50  (L50, nM)
Vasopressin 0.51 ± 0.09a 100 ± 0 10.05 ± 0.08b (0.089) 0.16 ± 0.02c 100 ± 0 7.68 ± 0.04d (21)
Oxytocin 0.56 ± 0.12a 110 ± 5 9.44 ± 0.13b (0.36) 0.16 ± 0.03c 97 ± 4 6.75 ± 0.08d (180)
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they contain too many parameters to be useful in medicinal chemistry campaigns.) The model is illustrated in 
Fig. 8. Signaling activity is quantified using a single, readily-measurable parameter, kτ, which is the initial rate 
of signaling by the agonist-bound receptor in enzymatic  terms33. The model is extended to incorporate known 
regulation of signaling mechanisms. GPCR signaling is regulated to limit signaling, preventing over-stimulation 
of the cell. We consider the properties of the model, how it relates to the model-free analysis, and how to estimate 
the efficacy and regulation parameters by curve fitting. The model gives rise to the four curve shapes observed 
experimentally. It emerged that the specific shape is simply dependent on the number of regulatory mecha-
nisms (0, straight line; 1, association exponential; 2, rise-and-fall to baseline). It is shown the model-free analysis 
emerges from the mechanistic model, the equations of the former being general forms of the equations for the 
latter. Estimating efficacy is straightforward and does not require knowledge of the mechanism—it is shown kτ is 
equal to IRmax . The regulation parameters can be estimated if the mechanism is known, for example the receptor 
desensitization rate constant.
Model description. The kinetic mechanistic model describes GPCR signaling in terms of enzyme activity. A 
signal results from conversion of a signal precursor (analogous to the substrate) to the signal (the product) by 
the agonist-bound GPCR (the enzyme) (Fig. 8), as described  previously33. The rate of ligand efficacy for generat-
ing the response is quantified as the initial rate of signaling, termed kτ, analogous to the initial rate of enzyme 
activity. kτ is the rate of response generation by the agonist-occupied receptor, defined as the product of the total 
receptor concentration ( [R]TOT ), total signal precursor ( EP) and the response-generation rate constant ( kE):
(By comparison, the initial rate of enzyme activity is the product of the enzyme concentration, substrate concen-
tration and the catalytic rate constant.) The model as formulated in this study assumes receptor-ligand occupancy 
does not change over time, that the equilibrium level of occupancy is rapidly achieved and is not rate-liming. This 
condition is likely met for maximally-stimulating ligand concentrations (used to quantify efficacy), and for all 
concentrations of lower potency ligands, scenarios which result in rapid association of ligand with receptor (see 
Discussion). Note the model framework is amenable to extension to incorporate the kinetics of receptor-ligand 
binding, as described  previously33.
The model can be extended to incorporate regulation of signaling. The canonical mechanisms are response 
degradation and receptor desensitization. Response degradation is the process by which the signal, once gen-
erated, is cleared over time. Examples include breakdown of second messenger molecules, such as cAMP by 
 phosphodiesterases37, and de-activation of G-protein by hydrolysis of bound GTP to GDP by the intrinsic GTPase 
activity of the G-protein89. Some signals are decreased by clearance of the signaling species from the relevant 
compartment, for example efflux of cytosolic  Ca2+  ions69. In the model, response degradation (pink region of 
Fig. 8) is represented simply by exponential decay, governed by kD , the response degradation rate constant. This 
component of the model was described  previously33.
kτ = [R]TOTEPkE
D
kD
R0A
kDES
Ep
E
RA
kτ
Figure 8.  Kinetic mechanistic model of agonism incorporating regulation of signaling. Both mechanisms 
of short-term signaling regulation are included – receptor desensitization (yellow) and response degradation 
(pink). The response generation process is in green. In this process, the response precursor ( EP ) is converted to 
the response ( E ) by the agonist-occupied receptor ( RA ). This proceeds at a rate defined by kτ , the transduction 
rate constant, which is the initial rate of response generation by the agonist-occupied receptor. Receptor 
desensitization is represented by transformation of RA into the inactive receptor R0A that does not generate a 
response (because it can’t couple to EP ). The rate constant for desensitization is kDES . Degradation of response 
is represented by decay of E to D , governed by the degradation rate constant kD. This model is an extension the 
original kinetic mechanistic  model33, extended here to incorporate receptor desensitization.
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Receptor desensitization model. In the present study, the model is extended to incorporate the second canoni-
cal regulation process, receptor desensitization (Fig. 8 yellow region). Receptor desensitization typically results 
from receptor phosphorylation and subsequent arrestin binding, which inhibits G-protein  interaction34–36. This 
process is represented simply as an exponential decay of the agonist-bound receptor concentration that can 
couple to the signaling machinery. This is governed by the desensitization rate constant, kDES . The basic model 
is formulated in Appendix 2.1 and is represented by Scheme 1 below:
The time course shape predicted by this model is an association exponential curve (Fig. 9b). This is consistent 
with experimental results; systems in which the sole regulation mechanism is receptor desensitization yield an 
association exponential time course. Examples include IP production by the  AT1 (Fig. 3a)40, PAR1 (see Fig. 2b 
 in41) and C-terminally-extended GnRH receptor (see Fig. 3c  in43) (when response degradation is blocked by  Li+). 
This curve shape makes sense intuitively. At early times response is generated rapidly. The response then slows, 
because response generation is attenuated by the loss of active receptor. Ultimately the response approaches a 
limit (the plateau). At this limit the response level does not change because no new response is being generated 
and the existing response is not degraded.
This model can now be extended to incorporate both regulation mechanisms, receptor desensitization and 
response degradation (Appendix 2.2), represented by Scheme 2 below:
The time course shape for this model is a rise-and-fall to baseline curve (Fig. 9e). This makes sense intuitively. 
The response rises rapidly then slows as receptor desensitization starts to slow the rate of response generation. 
The response becomes further limited owing to response degradation. The response reaches an upper limit (the 
peak) when the rate of response generation equals the rate of degradation. After this, response degradation pre-
dominates over response generation. Less and less new response is generated because the active receptor concen-
tration is declining, and ultimately no new response will be generated because the active receptor concentration 
will decline to zero. Ultimately the response level falls to zero once all existing response has been degraded. This 
profile is evident in systems where both mechanisms have been shown to be in operation. Examples include 
diacylglycerol production via the  AT1 receptor (Fig. 4a)65, cAMP accumulation via the β2 adrenoceptor in the 
absence of phosphodiesterase inhibition (Fig. 4b)53, and IP production via the CCK1 receptor in the absence of 
 Li+ (Fig. 10a  of90).
More complex models. More complex regulation and signaling mechanisms discovered experimentally can be 
represented using the model formulation, as described in Appendix 2.3. Receptor can resensitize and then con-
tribute to signaling. This model is formulated in combination with response degradation in Appendix 2.3.1. The 
receptor, once desensitized and internalized, can continue to signal from internal  compartments16–18. This model 
is formulated in Appendix 2.3.2. A third complex model describes calcium signaling; response is degraded 
(cleared from the cytoplasm) but the response can reform (from calcium that re-enters the cell). This process, in 
combination with depletion of the response precursor, is formulated in Appendix 2.3.3. In all three models the 
time course is described by a rise-and-fall to steady-state equation (see Appendix 2.3).
Comparison of models with experimental data. The receptor desensitization model completes the set of kinetic 
mechanistic signaling models developed for GPCRs, initiated in ref.33. This allows comparison of a complete 
kinetic model of GPCR signaling and regulation with experimental data, and with the model-free analysis. The 
model mechanisms are shown schematically in Fig. 9 and are: no regulation; receptor desensitization; response 
degradation; response recycling; receptor desensitization and response degradation; precursor depletion and 
response degradation; and the three more complicated models described above and in Appendix 2.3. Simulators 
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of the models are provided in Supporting Material, enabling investigators to evaluate changes of the parameter 
values.
The time course curve shapes predicted by the model are those observed experimentally – the straight line, the 
association exponential, and the two rise-and-fall curves (Fig. 9). It emerges that the shape is dependent on the 
number of regulatory mechanisms. With no regulatory mechanisms, the time course is a straight line (Fig. 9a). 
With one mechanism, an association exponential curve results (receptor desensitization, response degradation, 
or response recycling, Fig. 9b–d). With two mechanisms, a rise-and-fall to baseline curve results (Fig. 9e,f). 
More precisely, when an input regulation mechanism (desensitization or precursor depletion) is coupled with an 
output mechanism (response degradation). With the more complicated mechanisms, a rise-and-fall to baseline 
profile results (Fig. 9g–i).
Figure 9.  Kinetic signaling and regulation model time course simulations. Data were simulated using the 
model equations in Supplementary Tables S1–S4, with terms defined in Supplementary Table S5. Parameter 
values were: kτ , 20 response units; kDES , 0.15 min−1; kD , 0.2 min−1; kDEP , 0.3 min−1; kRES , 0.08 min−1; kτ1 , 20 
response units; kτ2 , 7 response units; kR , 0.07 min−1.
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Comparison of models with model‑free analysis. The four curve shapes of the mechanistic model are the same 
as those of the model-free analysis. This is shown graphically by comparing Fig. 9 with Fig. 1. It is also evident 
mathematically by inspection of the equations; the model equations listed in Supplementary Tables S1–S4 con-
form to the forms of the general equations (Eqs. 1–4). This finding indicates the model-free analysis emerges 
from known mechanisms of GPCR signaling and regulation.
The maximal initial rate from the model-free analysis ( IRmax ) is equal to kτ from the mechanistic model. This 
is evident by taking the initial rate of the equations, i.e. the limit as time approaches zero. By definition this limit 
is IRmax for the model-free analysis. For the mechanistic equations, this limit is kτ (for a maximally-stimulating 
concentration of agonist, Appendix 1.2). This supports the hypothesis that the initial rate is purely an efficacy 
term, being the rate of response generation before it is impacted by regulation of signaling mechanisms, because 
kτ contains efficacy terms but no regulation terms. It also provides a mechanistic foundation of IRmax , indicating 
it is analogous to the initial of an enzyme’s activity (formally, the product of the receptor and precursor concentra-
tions and a rate constant). Finally, this formulation demonstrates the maximal initial rate is system-dependent, 
being dependent on the receptor and precursor levels, which can differ between systems.
Measuring model parameters. The models contain parameters for signal generation and for regulation of sign-
aling. These parameters can be estimated by curve fitting by two methods. The time course data can be fit directly 
to equations that explicitly describe the model. These equations are listed in Supplementary Information and 
are provided in a custom Prism template in the supplementary files (“Signaling kinetic mechanism equations”). 
Alternatively, the data can be fit to general time course equations (Eqs. 1–4) and the fitted parameter values used 
to calculate the model parameters. These approaches are used here to estimate efficacy and regulation param-
eters, which can be done using just a maximally-stimulating concentration of agonist. Note in all the literature 
examples in this study, a maximally-stimulating concentration was used.
The general equation fitting approach is used here for the linear, association exponential, and rise-and-fall to 
baseline examples. For the linear examples, the only parameter to be estimated is kτ and this is equal to the slope 
of the line for a maximally-stimulating concentration of agonist. The resulting kτ values are the Slope values in 
Fig. 2 and Supplementary Fig. 1.
For the association exponential time course, there are two parameters, the efficacy parameter kτ, and a regula-
tion parameter specified by the model (for example, the desensitization rate constant kDES ). kτ can be estimated 
using the same method as that used in the model-free analysis to calculate IRmax , since these parameters are 
equivalent (see “Measuring the initial rate from curve fit parameters” above). The rate constant k is multiplied by 
the steady-state level of response, for a maximally-stimulating concentration of agonist. This resulting kτ values 
are equal to the initial rate values given in Fig. 3 and Supplementary Fig. 2, and the IRmax values in Table 1. Note 
in all the model variants that give rise to the association exponential profile, kτ is the product of k and the steady-
state response, i.e. kτ is calculated in the same way. This means kτ can be estimated without knowing the specific 
mechanism underlying the curve shape. The regulation parameter of the association exponential time course 
is dependent on the mechanism. In all cases, the regulation parameter is given by the rate constant parameter 
k of the general equation (Supplementary Table S2). If the mechanism is known, the value of k can be ascribed 
to a regulatory process. This is shown using the studies cited here where the regulation of signaling mechanism 
was evaluated. In Fig. 3a, IP generation by the  AT1  receptor40, the mechanism was most likely receptor desen-
sitization since deletion of arrestin changes the shape to a straight line (Fig. 2a) and response degradation was 
blocked by  Li+. The rate constant k then represents the desensitization rate constant kDES . The fitted value of 
0.040 min−1 indicated a receptor desensitization half time of 17 min. In Fig. 3b,c, the mechanism is most likely 
response degradation since receptor desensitization was minimized, the GnRH receptor lacking a C-terminal 
 tail45 (Fig. 3b), the β2 adrenoceptor-expressing cells devoid of  arrestin40 (Fig. 3c), and in both cases inhibitors of 
degradation excluded. The k value then represents the response degradation rate constant kD . The fitted values, 
0.12 min−1 for the  GnRH1 receptor and 1.1 min−1 for the β2 adrenoceptor, indicated response degradation half-
times of 5.8 min and 38 s, respectively.
For the rise-and-fall to baseline mechanisms, there are three parameters – the efficacy parameter kτ, and two 
regulation parameters. kτ can again be estimated using the general equation without knowing the specific mecha-
nism underlying the time course profile. kτ is equal to the parameter C of the general equation (Eq. 3) when a 
maximally-stimulating agonist concentration is employed, and these values are shown for the literature examples 
in Fig. 4. The rate constant values can be ascribed to the mechanism rate constants if the mechanism is known. 
In Fig. 4a, diacyglycerol production by the  AT1 receptor, the mechanism is most likely receptor desensitization 
and response degradation, since blocking arrestin recruitment changes the shape to an association exponential 
(see Fig. 2a of ref.65) and diacyclglycerol is rapidly degraded by diacylglycerol  kinases38. It is then necessary to 
determine which of the general rate constants ( k1 and k2 ) corresponds to which of the mechanism rate constants 
( kDES and kD ). In this case, it is likely the faster of the rates ( k1 ) corresponds to kD , since blocking arrestin recruit-
ment gives an association exponential profile with rate similar to k1 (see Fig. 2a of ref.65). This approach gives a 
kD ( k1 ) value of 5.5 min−1 and a kDES ( k2 ) value of 0.80 min−1, corresponding to degradation and desensitization 
half times of 7.6 s and 52 s, respectively. In Fig. 4c, cytoplasmic  Ca2+ elevation via the GnRH receptor, the mecha-
nism is most likely precursor depletion and response degradation, based on the known mechanism of calcium 
responses (see “Rise-and-fall to baseline time course profile” above). The more rapid of the two rate constants is 
most likely precursor depletion since this is the first event in the signaling cascade. This logic gives a kDEP ( k1 ) 
value of 0.46 s−1 and a kD ( k2 ) value of 0.072 s−1, corresponding to depletion and degradation half times of 1.5 s 
and 9.6 s, respectively. Figure 4b shows cAMP generation by the β2 adrenoceptor. In this example, likely resulting 
from receptor desensitization and response degradation based on the experiments in ref.53, the two rate constant 
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values are close to one another (1.5 and 0.96 min−1), preventing the ascribing of the constants to the regulatory 
processes but demonstrating the rate of the processes is similar in this system.
For the rise-and-fall to steady-state models, kτ can be estimated using the general equation and a maximally-
stimulating concentration of agonist. kτ is equal to IRmax , calculated from the parameters as described above. 
For estimating the regulation parameters, we recommend using the mechanistic model equation rather than the 
general equation. For this curve shape, the general equation parameters correspond to complicated combinations 
of the mechanism parameters, which introduces constraints of the parameter values that are not incorporated 
into the general model equations (Appendix 2.3). This approach was used to analyze the  Ca2+ mobilization data 
in Fig. 5a. In this experiment,  Ca2+ was included in the extracellular medium, which results in a steady-state 
being reached between cytoplasmic  Ca2+ entry and export. This is the “Response degradation to steady-state with 
precursor depletion” model (Appendix 2.3.3). The equation (Eq. (17), see Methods) fitted the data well  (R2 value 
0.995, see curve in Fig. 5a, standard error of the fitted model parameters less than 10%—see “Curve fit results” 
Excel file in Supporting Material). The regulation rate constant values were 0.37 s−1 for kDEP , 0.052 s−1 for kD 
and 0.0033 s−1 for kR , corresponding to half times for precursor depletion, response degradation and response 
reformation of 1.9 s, 13 s and 3.5 min, respectively. As expected, the kτ value from the mechanism equation fit 
was the same as the value from the model-free analysis (240 nM s−1).
Discussion
New technologies have enabled efficient measurement of the kinetics of GPCR signaling using continuous-read, 
real-time bioassay  modalities12–14. Methods are now required to extract pharmacological parameters from the 
time course data. Such methods have been developed for specific responses that are immediately proximal to 
the receptor  (internalization25 and arrestin-receptor  interaction26). Here methods were designed for universal 
application to GPCR signaling and regulation responses. Curve-fitting methods are described for analyzing time 
course signaling data, designed for routine use by pharmacologists, enabling application to medicinal chemistry 
and receptor research. These models could account for a broad array of historical time course signaling data. 
The equations are simple and built into commonly-used curve-fitting programs, or are provided in ready-to-use 
templates. The efficacy for signaling is quantified kinetically by an intuitive, familiar and biologically meaningful 
parameter, the initial rate of signaling, which is obtained from the curve fit parameters. The underlying theoreti-
cal framework is familiar, based on the concepts of enzyme kinetics and the known mechanisms of regulation 
of signaling. Resources are provided in Supporting Material to facilitate implementation and application of the 
models, including Prism templates containing the equations, and a time course data simulator for the mechanistic 
models. With these new analysis tools, the model can be tested prospectively using new data, testing the effects 
of regulation of signaling, evaluating how the initial rate characterization compares with historical single time 
point pharmacological methods, and investigating the effect of receptor reserve (see below).
This approach has practical benefits for optimization of new molecules and for GPCR signaling research. 
In project workflow, it allows representation of the time course data set by a minimal number of informative 
parameters (e.g. kτ, kDES ). This enables tabulation of kinetic signaling data for a series of ligands, necessary for 
medicinal chemists to establish kinetic structure–activity relationships. If the response at a specific time point 
is required, for example when comparing in vivo and in vitro activity, this can be calculated from the curve 
fit parameters, avoiding the necessity of measuring precisely the same time points in every experiment. The 
approach solves the time-dependency problem, in which pharmacological parameter values can be dependent 
on the time point at which they are measured, complicating quantification of efficacy and biased  agonism24–26. 
This is because: (1) Activity is quantified as a rate constant value, which is constant over time; (2) Differences 
of curve shape can be accommodated because the same efficacy parameter, the initial rate, can be extracted 
from all four of the commonly-encountered time course curve shapes. Finally, the method separates efficacy 
and regulation, allowing these parameters to be quantified separately (e.g. kτ and kDES ), enabling independent 
structure–activity optimization of these processes.
The mechanistic model yields insights that explain the time course curve shapes and provide mechanistic 
meaning to the parameters from the model-free analysis. The model and experimental data show that regula-
tion of signaling defines the time course curve shape. Regulation changes the shape from a straight line (where 
response is generated indefinitely), to an association exponential curve or a rise-and-fall curve, with the type of 
curve dependent on the number and nature of the regulation mechanisms (Fig. 9). The underlying mechanism 
can be interrogated by blocking receptor desensitization and/or response degradation. The model supports the 
hypothesis that the initial rate of activity is purely an efficacy term, unaffected by regulation of signaling: It is 
shown that kτ, devoid of regulation terms, is the limit of the equations as time approaches zero, the formal defi-
nition of the initial rate (Appendix 1). The model translates the empirical parameters of the model-free analysis 
into biologically-meaningful parameters of GPCR signaling mechanisms. IRmax is equivalent to kτ, the initial 
rate of signaling generation by the agonist occupied receptor, analogous to the initial rate of an enzyme’s activity. 
The rate constants k , k1 and k2 correspond simply to the rate constants of the regulation processes, e.g. receptor 
desensitization and response degradation. If the mechanism is known, the rate constant value can be assigned 
to a regulatory activity, enabling regulation of signaling to be quantified in simple, kinetic terms.
The relationship between the kinetic analysis and existing pharmacological analysis is now considered. Estab-
lished pharmacological analysis quantifies signaling in terms of efficacy and affinity, usually at a single time 
point at which equilibrium between receptor and ligand is  assumed3–8. The efficacy term in the kinetic approach 
( IRmax or kτ) is a direct analogue of established efficacy parameters  (Emax, and τ of the operational  model7). 
Consequently, the rank order of efficacy should be the same using both approaches. Affinity is more difficult 
to measure using the kinetic approach because of the equilibration issue. Properly measuring affinity from a 
concentration–response requires the assay to be incubated long enough for equilibrium between receptor and 
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ligand to be closely  approached91. By contrast, the initial rate in the kinetic method is quantified using the earliest 
time points after the addition of ligand and under these conditions it cannot be generally assumed the ligand and 
receptor are at  equilibrium5,33,92,93. The impact can be evaluated by considering typical values of receptor-ligand 
binding rate constants, using the mass-action receptor-ligand association kinetics  equation94. For low affinity 
ligands, the equilibration time is short, potentially enabling accurate estimation of affinity when using responses 
that proceed over several minutes. A compound with 10 μM affinity, binding with an association rate constant 
( kon ) of  108 M−1 min−1, reaches 97% of its equilibrium occupancy within 0.1 s at its Kd concentration (i.e. 10 μM). 
However, for high affinity ligands the equilibration time can be long relative to the duration of the response. A 
compound with 1 nM affinity and a kon of  108 M−1 min−1 takes 18 min to reach 97% of its equilibrium receptor 
occupancy when applied at its Kd concentration. The problem is magnified when the response is very rapid, as 
previously  described92, particularly in  Ca2+ signaling, which proceeds in seconds. This issue can be circumvented 
when receptor and ligand can be pre-incubated prior to the initiation of the response, for example in GTPγS 
binding assays, but this option is rarely available in whole cell assays, the most commonly used assay modality. 
Importantly, this issue does not affect estimation of efficacy. IRmax and kτ are estimated using maximally-effective 
concentrations which, due to mass action, bind more rapidly. For example, when applied at 10 μM concentration, 
the 1 nM Kd ,  108 M−1 min−1 kon compound reaches 97% of equilibrium occupancy within 0.2 s. Finally, the effect 
of signal amplification, manifest as receptor reserve, in the kinetic mechanistic model requires further investiga-
tion. While the model can incorporate receptor reserve intrinsically (as a depletion of response precursor)33, 
the rate of signaling in a multistep pathway is ultimately a function of the rates of the individual steps and the 
stoichiometric relationships between them. For example, the initial rate could be susceptible to receptor reserve 
effects if there is a rate-limiting step upstream of the response being measured. This issue requires experimental 
investigation.
In conclusion, this study introduces straightforward data analysis methods to quantify the kinetics of GPCR 
signaling. The simplicity of the analysis procedures, the intuitive nature of the parameters, and the mechanistic 
foundation in known and emerging GPCR signaling paradigms will facilitate pharmacological discovery and 
optimization in kinetic terms.
Methods
extraction of time course data. Data were extracted from figures in published articles using a plot digi-
tizer (Graph Grabber v2, Quintessa Limited, Henley-on-Thames, UK).
Equations for model-free analysis. For model-free analysis, time course data were fit to empirical time 
course equations. The following equations were used when the response started at the moment of ligand addi-
tion. The straight line equation is Eq. (1),
where y is response, Slope is the gradient of the line and t is the time of response measurement. Baseline is the 
response in the absence of ligand. Note Baseline is assumed to remain constant over time. The correspond-
ing equation in Prism is named “Straight line” and the parameter Yintercept in this equation corresponds to 
 Baseline50.
The association exponential equation is Eq. (2):
where SSR is the steady-state response, specifically the ligand-specific response as time approaches infinity. Note 
the y asymptote value as time approaches infinity is SSR + Baseline. k is the observed rate constant in units of t−1. 
The corresponding equation in Prism 8 is named “One-phase association,”61 in which Span corresponds to SSR, 
Y0 corresponds to Baseline, and Plateau corresponds to SSR + Baseline.
The rise-and-fall to baseline equation is Eq. (3):
where C is a fitting constant in units of y-units.t−1 (which is the initial rate of signaling, see Appendix 1.1) and k1 
and k2 are observed rate constants in units of t−1. In the analysis, k1 is the larger of the two rate constant values, 
constrained to be greater than k2 (see “Fitting procedures” below). This equation has been loaded into a Prism 
template as a user-defined equation named “Rise-and-fall to baseline time course” (see “Signaling kinetic model-
free equations” file available in the supplementary files).
The rise-and-fall to steady-state equation is Eq. (4):
where, as above, SSR is the steady-state response, specifically the ligand-specific response as time approaches 
infinity. Note the y asymptote value as time approaches infinity is SSR + Baseline. D is a unitless fitting constant, 
and k1 and k2 are observed rate constants in units of t−1. In the analysis, k1 is the larger of the two rate constant 
values, constrained to be greater than k2 (see “Fitting procedures” below). This equation has been loaded into 
a Prism template as a user-defined equation named “Rise-and-fall to steady state time course” in which the 
(1)y = Slope× t + Baseline
(2)y = SSR ×
(
1− e−kt
)
+ Baseline
(3)y =
C
k1 − k2
(
e−k2t − e−k1t
)
+ Baseline
(4)y = SSR ×
(
1− De−k1t + (D− 1)e−k2t
)
+ Baseline
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parameter SteadyState corresponds to SSR (see “Signaling kinetic model-free equations” file available in the 
supplementary files).
In certain circumstances it is desirable to float the initiation of signaling time in the analysis. This enables 
the analysis to accommodate slight uncertainty as to the precise time point of ligand addition, especially for 
rapidly-generated signals. It also allows for signaling mechanisms where there is a delay between ligand-receptor 
binding and initiation of detectable signaling, often observed in gene expression assays, and thought to be due 
to a necessary build-up of signal transduction intermediates to a threshold  level48. When floating the start time 
in the analysis it is necessary to establish the baseline response level prior to the start time. Equations 1–4 above 
can be adapted to incorporate a fitted start time, the corresponding equations being Eqs. (5–8) below:
where t0 is the signal initiation time and t is time uncorrected for the signal initiation time. Equation (6) is 
equivalent to the equation named “Plateau followed by one phase association” in Prism 8, in which Span corre-
sponds to SSR and Y0 corresponds to  Baseline95. Equations 5,7 and 8 have been loaded into a Prism template as 
User-defined equations named “Baseline then straight line time course”, “Baseline then rise-and-fall to baseline 
time course” and “Baseline then rise-and-fall to steady state time course” respectively (see “Signaling kinetic 
model-free equations” Prism file available in the supplementary files). In Prism the equations are coded with an 
IF statement to fit the baseline before t0 . For example, Eq. (7) is written in Prism as,
In some cases, stimulation of signaling results in a decrease of response signal. In other words, the detected 
response signal decreases over time. This can result from technical considerations, for example, certain biosensors 
decrease in signal upon binding the response analyte (so called “Downward” sensors). It can also result from the 
signaling mechanism, for example stimulation of  Gi is often detected by the resulting inhibition of cAMP accu-
mulation. This can be handled by taking the inverse of the detected signal and plotting this versus time (creating 
an “Upward” time course, see for example Supplementary Fig. S2d). Alternatively, downward data can be fit to 
the downward analogue of the equations. Examples of this approach are used in this study (inhibition of cAMP 
accumulation, see Supplementary Fig. S2f, and GIRK channel currents, see Supplementary Fig. S2h); data were 
analyzed with the downward analogue of the association exponential equation, which is the exponential decay 
equation shown below (Eq. 9):
Note the response at t = 0 is equal to SSR + Baseline. The corresponding equation in Prism 8 is named “Pla-
teau followed by one phase decay,” in which Span corresponds to SSR, Plateau corresponds to Baseline, and Y0 
corresponds to SSR + Baseline96.
calculation of initial rate. The initial rate of signaling was determined by first fitting the data to the time 
course equations, then using the fitted parameter values to calculate the initial rate ( IR ). This calculation utilized 
an equation defining the initial rate in terms of the fitted parameters, the equation obtained by taking the limit 
of the time course equation as time approaches zero (the formal definition of the initial rate condition). These 
equations were derived in Appendix 1:
Straight line:
Association exponential:
Rise-and-fall to baseline:
Rise-and-fall to steady-state:
Equations for kinetic mechanistic model analysis and simulation. The kinetic mechanistic model 
was used to simulate and analyze time course data using the model equations, derived in Ref.33 and Appendix 2. 
(5)y = Slope× (t − t0)+ Baseline
(6)y = SSR ×
(
1− e−k(t−t0)
)
+ Baseline
(7)y =
C
k1 − k2
(
e−k2(t−t0) − e−k1(t−t0)
)
+ Baseline
(8)y = SSR ×
(
1− De−k1(t−t0) + (D− 1)e−k2(t−t0)
)
+ Baseline
Y = IF
(
X < X0, Baseline, Baseline + (C/(K1− K2)) ∗
(
exp(−K2 ∗ (X− X0))− exp(−K1 ∗ (X− X0))
))
(9)y = SSR × e−k(t−t0) + Baseline
IR = Slope
IR = SSR × k
IR = C
IR = SSR × (Dk1 − (D− 1)k2)
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The equations employed are given in Supplementary Tables S1–S4 and are listed in Supplementary information. 
A Prism template containing the equations called “Signaling kinetic mechanism equations” is available in the 
supplementary files. The terms in the models are defined in Supplementary Table S5. Data in Fig. 5a  (Ca2+ mobi-
lization via the  GnRH1 receptor) were analyzed using the equation for the precursor depletion & response deg-
radation to steady-state model (Eq. (16), Appendix 2.3.3) that incorporated a variable signal initiation time ( t0):
where,
fitting procedures. Data were fit by nonlinear regression to the equations using Prism 8. In almost all 
cases, the default fitting settings were used, specifically least-squares nonlinear regression with medium con-
vergence criteria, no special handling of outliers and no  weighting78. In two cases, Figs. 4b and 5b, the default 
settings yielded an ambiguous fit, in that some of the parameter values were not resolved (see “Curve fit results” 
Excel file in Supporting Material)79. In these cases, unambiguous parameter values were obtained using the 
“Robust regression” option which minimizes the contribution of outliers to the  fit74. In the rise-and-fall fits 
(Eqs. 3, 4, 7, 8), which contain two rate constants k1 and k2 , k1 was assumed to be the larger of the rate constant 
values and this was handled by constraining k1 to be greater than k2 . In all cases, rate constant values were con-
strained to be greater than zero. The fitted values, the standard error and the correlation coefficient  R2 are given 
in the “Curve fit results” Excel file in Supporting Material. Values were given to four significant figures. When the 
signal initiation time was floated (Eqs. 5–9), the initial value (X0) was entered manually.
In order to obtain an estimate of the error of the fitted parameters, the standard error was computed as 
 described51, assuming a symmetrical confidence interval. This required changing the default “Calculate CI or 
parameters” from asymmetrical to symmetrical in the “Confidence”  dialogue97.
The baseline response, that in the absence of ligand, was handled by incorporating a baseline term into the 
equations and fitting this parameter as part of the analysis. A commonly-used alternative, subtracting baseline 
from the data set and excluding the baseline term from the equation, was found to distort the fit significantly 
for the rise-and-fall to baseline equation, unless the subtracted baseline value was in very close agreement with 
that determined by incorporating the baseline into the curve-fitting procedure.
For the  V2 vasopressin receptor experiments, the biosensor fluorescence intensity data were normalized 
to baseline. Specifically, response was quantified as the fluorescence after ligand addition divided by the mean 
baseline signal before addition, a metric termed F/ΔF. (The mean baseline signal is the mean of the fluorescence 
intensity measurements before ligand addition.) The data was handled in this way because it provides a conveni-
ent intra-well control, minimizing error due to any slight well-to-well differences in the amount of sensor or 
number of cells. The arrestin sensor data was inverted by calculating the value 1 − F/ΔF. This was done because 
the arrestin sensor is a downward sensor (a decrease in fluorescence resulted from receptor interaction)26. In the 
fitting procedure, each technical replicate was considered an individual point.
Concentration–response data for the initial rate were fit to a sigmoid curve equation, the “Log(agonist) vs. 
response − Variable slope” equation in  Prism83:
The “Bottom” parameter was constrained to zero. (Note in the Prism formulation,  L50 is written as  EC50. The  EC50 
term is not used here because it has an explicit pharmacological  definition62.)
Measurement of cAMp generation and arrestin recruitment using biosensors. Genetically-
encoded biosensors were used to measure cAMP generation and arrestin recruitment via the  V2 vasopressin 
receptor. The sensors have been described previously (red cADDis for  cAMP82 and see ref.26. for arrestin recruit-
ment), and are packaged in the BacMam vector for delivery to cells. The cDNA for the  V2 vasopressin receptor 
was obtained from the cDNA Resource Center (Bloomsburg University, Bloomsburg, PA). The experiments were 
conducted in HEK293T cells transfected with the receptor and each sensor individually (i.e. one batch of cells 
with receptor and the cAMP sensor and a separate batch with receptor and arrestin sensor). HEK 293T cells were 
cultured in Eagle’s minimum essential media (EMEM) supplemented with 10% fetal bovine serum (FBS) and 
penicillin–streptomycin at 37 °C in 5%  CO2. One day before the transfection, HEK293T cells were seeded at a 
density of 27,000 cells/well in a 96-well plate (Greiner Cellcoat #655946). Approximately 16–20 h later, cells were 
transfected with 50 ng of the  V2 receptor plasmid per well, using Lipofectamine 2000 from Invitrogen (Waltham, 
MA USA). After an approximately 4 h incubation period at 37 °C and 5%  CO2, the transfection mix was replaced 
with 100uL complete cell culture media and the cells were allowed to recover for approximately 1.5 h under 
normal growth conditions. The cells were then transduced with either the red cADDis or green arrestin sensor 
BacMam stocks. To prepare the transduction mixture, the BacMam containing cADDis or the arrestin sensor, 
2 mM sodium butyrate, and EMEM were combined in a final volume of 50 μL. For each experiment, 6.18 × 108 
viral genes of cADDis virus or 4.24 × 108 viral genes of arrestin sensor virus were added to each well. The 50 uL 
(17)
Et = if
(
t < t0, Baseline, Baseline+
kτ kR
kD(obs)kDEP
[
1−
kDEP
kDEP − kD(obs)
e
−kD(obs)(t−t0) +
kD(obs)
kDEP − kD(obs)
e
−kDEP(t−t0)
]
+
kτ
kDEP − kD(obs)
(
e
−kD(obs)(t−t0) − e
−kDEP (t−t0)
))
kD(obs) = kR + kD
y = Bottom+
Top− Bottom
1+ 10(LogL50−x)×HillSlope
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transduction mixture was then added to the 96-well plate (50 uL/well) and incubated for approximately 24 h at 
37 °C in 5%  CO2.
Thirty minutes prior to fluorescence plate reader experiments, the media in each well was replaced with 
150 μL of Dulbecco’s phosphate buffered saline (DPBS) supplemented with  Ca2+ (0.9 mM) and  Mg2+ (0.5 mM). 
Fluorescence plate reader experiments were performed on the Synergy Mx reader (BioTek, Winooski, VT). The 
green fluorescence detection was recorded using 488/20 nm excitation and 525/20 nm fluorescence emission, 
while red fluorescence detection was recorded using 565/20 nm excitation wavelength and 603/20 nm fluores-
cence emission. After acquiring the baseline fluorescence for several minutes, drug was added manually with a 
multichannel pipette in a volume of 50 µL at the indicated time points.
Oxytocin and vasopressin were obtained from Cayman Chemical (Ann Arbor, MI USA). All working con-
centration of drugs were dissolved in DPBS and added manually to the HEK 293T cells at the indicated concen-
trations and time points.
Statistical analysis. Concentration–response data for  V2 vasopressin receptor responses to vasopressin 
and oxytocin were compared statistically by paired, two-tailed t-test using Prism 8. Comparisons were per-
formed for maximal effect and  L50 (Tables 1, 2).
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